Clover Health Investments, Corp. is a healthcare company that operates Medicare Advantage plans and provides technology-enabled care management services. The company offers Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare beneficiaries, focusing on wide physician networks and low out-of-pocket costs. Its core technology, Clover Assistant, is a cloud-based software platform that uses machine learning and artificial intelligence to provide physicians with real-time, data-driven insights for chronic disease management. Clover Health also operates Clover Home Care, a longitudinal home-based primary care program for high-acuity members, and Counterpart Health, a subsidiary that licenses the Clover Assistant platform externally to other payors and providers as a Software-as-a-Service solution. The company serves Medicare-eligible seniors in the United States, specifically operating in five states and numerous counties, with a focus on underserved markets and patients with chronic conditions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Healthcare Plans Homepage cloverhealth.com
Sector Healthcare IR page investors.cloverhealth.com
Tags
medicare advantage, chronic disease management, clinical decision support, home-based primary care, healthcare software, pso plans, hmo plans, ai-powered care management, Clover Assistant, Counterpart Assistant, Clover Home Care, Counterpart Health Inc.
Press page —

Metrics

Valuation  
Market cap $ 2.771B
Market cap (USD) $ 2.771B
P/E 222.54
PEG —
P/BV 7.09
P/S 1.01
P/OCF 20.48
P/FCF 20.95
Dividend yield —
Turnover / mcap —
Returns  
ROE -26.3%
ROI -27.7%
ROIC -20.8%
Profit margin -4.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 1.924B 1.371B 2.034B 3.477B 1.472B —
Net profit -85.549M -43.009M -213.361M -338.844M -587.756M -6.745M
Free cash flow -68.977M 33.289M -116.455M -208.393M -283.049M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.35 3.15 0.95 0.93 3.72 16.77
Price performance 12m -0.25 2.31 0.02 -0.75 -0.78 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 20.8M 0.00 — — — —
Borrowings, non-current (USD) — — 106M 19.9M 0.00 — — —
Lease liabilities (USD) — — 4.8M 7.89M 5.86M 4.66M 3.33M 3.3M
Cash and deposits (USD) 75.4M 0.00 28M 300M 104M 123M 195M 78.3M
Right-of-use assets (USD) — — 7.88M 5.37M 4.03M 3.38M — —
Net debt (borrowings + leases - cash) (USD) — — 18.9M -272M -97.9M — — —
Cash flow detail
Operating cash flow (USD) — -160M -2.23M -282M -204M -116M 34.8M -66.9M
Purchases of property, plant and equipment (USD) — -23,000 -693,000 -723,000 -4.47M -584,000 -1.56M -2.04M
Change in receivables (cash effect) (USD) — -14.5M -12.9M -9.3M -22.6M 6.44M 12.6M -43.3M
Change in payables (cash effect) (USD) — 6.3M 10.8M 5.31M 7.64M 4.74M -2.62M 1.65M
Share buybacks (cash effect) (USD) — 0.00 0.00 -147,000 -6.36M -6.22M -1.77M -18.3M
Interest paid (cash effect) (USD) — -6.26M -4.58M -1.68M 0.00 0.00 — —
Income taxes paid (cash effect) (USD) — — — — — — — 0.00
Share-based compensation (USD) — 3.3M 7.08M 164M 164M 141M 114M 104M
Operating cash flow before change in receivables (USD) — -145M -106M -273M -181M -122M 22.2M -23.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -160M -119M -283M -208M -116M 33.3M -69M
Income detail
Total comprehensive income (USD) — -364M -136M -590M -346M -206M -42.2M -83.4M
Comprehensive income to owners (USD) — -364M -136M -590M -346M -206M -42.2M -83.4M
Reported Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Mar 1, 2023 Mar 14, 2024 Mar 3, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 16, 2026, Clover Health Investments, Corp. (the “Company”) published a list of responses to a selection of frequently asked supplemental questions submitted in connection with the Company's third quarter 2026 earnings announcement in order to further engagement with the Company's shareholder base. The supplemental questions and the Company's accompanying written responses are furnished as Exhibit 99.1 to this Current Report on Form 8-K, and are also available on the investor relations section of the Company's website.

Clover Health Reports Third Quarter 2026 Results Bull 5 Bear 0 Results

Business Highlights:

•Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth

•Improved Full Year 2026 guidance across all metrics

•2027 AEP tracking well, with significant growth due to strong product positioning in core markets

•Clover’s flagship PPO, representing ~98% of current membership, received a 5 Star rating for Payment Year 2028

Financial Results:

•Third quarter 2026 GAAP Net Income of $6 million, an improvement of $31 million year-over-year

•Third quarter 2026 Medicare Advantage membership of 158,907, up 45% year-over-year, and Total revenues of $759 million, up 53% year-over-year

•Third quarter 2026 Consolidated Gross Profit of $130 million, up 77% year-over-year, and Adjusted EBITDA of $16 million, up $14 million year-over-year

Improved Full Year 2026 Guidance:

•Average Medicare Advantage membership of 157,000 - 158,000, representing 47% growth year-over-year at the midpoint

•Total revenues between $2.97 billion and $3.00 billion, representing 55% growth year-over-year at the midpoint

•GAAP Net Income between $25 million and $35 million

•Consolidated Gross Profit

October 26, 2026

PDF Version

WILMINGTON, Del., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 12:30 p.m. Eastern Time.

A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/.

About Clover Health: Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations: Ryan Schmidt [email protected]

Press Inquiries: [email protected]

Search Investor Relations

×

Prompts

Clover Health Investments, Corp. (ticker CLOV), listed in United States.

Company History

Date Change Detail
Nov 17, 2020 Renamed SOCIAL CAPITAL HEDOSOPHIA HOLDINGS CORP. III → CLOVER HEALTH INVESTMENTS, CORP. /DE

ETFs Holding Clover Health Investments, Corp.

ETF Weight in ETF Shares Market value As of
HYP 2.78% 366,103 $ 1.918M Jun 30, 2026
SYZ 0.78% 101,994 $ 534.449K Jun 30, 2026
RESM 0.10% 694 $ 3,636.56 Jun 30, 2026
VFMO 0.07% 333,347 $ 1.383M Aug 31, 2026
AVIE 0.05% 1,595 $ 7,895.25 Nov 16, 2026
VFMF 0.05% 116,247 $ 482.425K Aug 31, 2026
DFAS 0.02% 1,434,676 $ 7.001M Nov 12, 2026
MSSM 0.01% 25,513 $ 105.879K Aug 31, 2026
DXUV 0.01% 110,536 $ 539.416K Nov 12, 2026
DFSU 0.01% 37,041 $ 180.76K Nov 12, 2026
DFUS 0.00% 143,928 $ 702.369K Nov 12, 2026
DFAC 0.00% 460,446 $ 2.247M Nov 12, 2026
DCOR 0.00% 224,826 $ 1.097M Nov 12, 2026
DFAU 0.00% 10,570 $ 51.582K Nov 12, 2026
AVUS 0.00% 4,132 $ 20.453K Nov 16, 2026
AVSC 0.00% 10,690 $ 52.916K Nov 16, 2026